TY - JOUR
T1 - The widening sphere of influence of HOXB7 in solid tumors
AU - Errico, Maria Cristina
AU - Jin, Kideok
AU - Sukumar, Saraswati
AU - Caré, Alessandra
N1 - Publisher Copyright:
© 2016 American Association for Cancer Research.
PY - 2016/5/15
Y1 - 2016/5/15
N2 - Strong lines of evidence have established a critical role for the homeodomain protein HOXB7 in cancer. Specifically, molecular and cellular studies have demonstrated that HOXB7 is a master regulatory gene, capable of orchestrating a variety of target molecules, resulting in the activation of several oncogenic pathways. HOXB7 overexpression correlates with clinical progression and poor outcome of cancer patients. Specific inhibition of HOXB7 is particularly relevant in cancers still lacking effective therapies, such as tamoxifen-resistant breast cancer and melanoma. Mechanistic studies are providing additional targets of therapy, and biomarker studies are further establishing its importance in early diagnosis and prognosis.
AB - Strong lines of evidence have established a critical role for the homeodomain protein HOXB7 in cancer. Specifically, molecular and cellular studies have demonstrated that HOXB7 is a master regulatory gene, capable of orchestrating a variety of target molecules, resulting in the activation of several oncogenic pathways. HOXB7 overexpression correlates with clinical progression and poor outcome of cancer patients. Specific inhibition of HOXB7 is particularly relevant in cancers still lacking effective therapies, such as tamoxifen-resistant breast cancer and melanoma. Mechanistic studies are providing additional targets of therapy, and biomarker studies are further establishing its importance in early diagnosis and prognosis.
UR - http://www.scopus.com/inward/record.url?scp=84971556291&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84971556291&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-15-3444
DO - 10.1158/0008-5472.CAN-15-3444
M3 - Review article
C2 - 27197229
AN - SCOPUS:84971556291
VL - 76
SP - 2857
EP - 2862
JO - Cancer Research
JF - Cancer Research
SN - 0008-5472
IS - 10
ER -